Package 69680-180-30

{"route": ["ORAL"], "spl_id": "320e2f48-a1d3-42c0-a482-c6982f9ef1ea", "openfda": {"nui": ["N0000008486", "N0000185506", "N0000182140"], "upc": ["0369680179308", "0369680177304", "0369680178301", "0369680181301", "0369680180304"], "unii": ["0H73WJJ391"], "rxcui": ["1494769", "1812419", "1812421", "1812425", "1812427"], "spl_set_id": ["a9d7c5ef-daf9-4f97-8673-7f4a2007f408"], "pharm_class_pe": ["Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "pharm_class_moa": ["Cytochrome P450 3A4 Inducers [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]"], "manufacturer_name": ["Vitruvias Therapeutics, Inc."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (69680-180-30)", "package_ndc": "69680-180-30", "marketing_start_date": "20250407"}], "brand_name": "Topiramate", "product_id": "69680-180_320e2f48-a1d3-42c0-a482-c6982f9ef1ea", "dosage_form": "CAPSULE, EXTENDED RELEASE", "pharm_class": ["Cytochrome P450 2C19 Inhibitors [MoA]", "Cytochrome P450 3A4 Inducers [MoA]", "Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "product_ndc": "69680-180", "generic_name": "Topiramate", "labeler_name": "Vitruvias Therapeutics, Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Topiramate", "active_ingredients": [{"name": "TOPIRAMATE", "strength": "150 mg/1"}], "application_number": "ANDA215638", "marketing_category": "ANDA", "marketing_start_date": "20250407", "listing_expiration_date": "20261231"}